[
  {
    "ts": null,
    "headline": "J.P. Morgan Sees Strong Q2 for Eli Lilly, Maintains Overweight Rating",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the high-margin pharma stocks to buy now. Eli Lilly and Company (NYSE:LLY) is set to report second-quarter results on August 7, and J.P. Morgan’s Chris Schott believes the stage is set for another strong showing. In a recent note, Schott outlined what he calls an “attractive setup” […]",
    "url": "https://finnhub.io/api/news?id=a51afc7c8d667237d782510e2f42747cf36d8e0ad7c3552af5d9d6162c7521b1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752864352,
      "headline": "J.P. Morgan Sees Strong Q2 for Eli Lilly, Maintains Overweight Rating",
      "id": 136011761,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of the high-margin pharma stocks to buy now. Eli Lilly and Company (NYSE:LLY) is set to report second-quarter results on August 7, and J.P. Morgan’s Chris Schott believes the stage is set for another strong showing. In a recent note, Schott outlined what he calls an “attractive setup” […]",
      "url": "https://finnhub.io/api/news?id=a51afc7c8d667237d782510e2f42747cf36d8e0ad7c3552af5d9d6162c7521b1"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
    "summary": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=10ef1dd32da56b51c9e208aa46d5076395ec37475bc144374bd2c2d563b6c483",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752856260,
      "headline": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
      "id": 136041280,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=10ef1dd32da56b51c9e208aa46d5076395ec37475bc144374bd2c2d563b6c483"
    }
  },
  {
    "ts": null,
    "headline": "Can Wegovy & Ozempic Drive Another Strong Quarter for Novo Nordisk?",
    "summary": "Wegovy and Ozempic drive 66% of NVO's Q1 revenues - investors eye Q2 sales ahead of results on Aug. 6.",
    "url": "https://finnhub.io/api/news?id=9fa67786cdd95cd2bca8fc1544e12476db4968112863bd4c9e52004d2827d1fb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752845940,
      "headline": "Can Wegovy & Ozempic Drive Another Strong Quarter for Novo Nordisk?",
      "id": 136005374,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Wegovy and Ozempic drive 66% of NVO's Q1 revenues - investors eye Q2 sales ahead of results on Aug. 6.",
      "url": "https://finnhub.io/api/news?id=9fa67786cdd95cd2bca8fc1544e12476db4968112863bd4c9e52004d2827d1fb"
    }
  },
  {
    "ts": null,
    "headline": "Brokers Suggest Investing in Lilly (LLY): Read This Before Placing a Bet",
    "summary": "The average brokerage recommendation (ABR) for Lilly (LLY) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?",
    "url": "https://finnhub.io/api/news?id=19dd27e8f56655e550872ef20d07ba1d8749807cee44bb258c248a82e22d8612",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752845403,
      "headline": "Brokers Suggest Investing in Lilly (LLY): Read This Before Placing a Bet",
      "id": 136005375,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The average brokerage recommendation (ABR) for Lilly (LLY) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?",
      "url": "https://finnhub.io/api/news?id=19dd27e8f56655e550872ef20d07ba1d8749807cee44bb258c248a82e22d8612"
    }
  },
  {
    "ts": null,
    "headline": "Can Eli Lilly Stock Withstand the Threat of President Trump's New Sweeping Tariffs?",
    "summary": "President Trump has threatened to levy tariffs of up to 200% on pharmaceutical imports.  Lilly's margins could be negatively affected if the company absorbs the higher costs.  The active ingredients of roughly 80% of prescription drugs sold in the U.S. are made in other countries.",
    "url": "https://finnhub.io/api/news?id=41188ca1eb21588a7d6a4618c56aa39295dad097da2dabfc5ebd936d9befee48",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752828420,
      "headline": "Can Eli Lilly Stock Withstand the Threat of President Trump's New Sweeping Tariffs?",
      "id": 136005376,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "President Trump has threatened to levy tariffs of up to 200% on pharmaceutical imports.  Lilly's margins could be negatively affected if the company absorbs the higher costs.  The active ingredients of roughly 80% of prescription drugs sold in the U.S. are made in other countries.",
      "url": "https://finnhub.io/api/news?id=41188ca1eb21588a7d6a4618c56aa39295dad097da2dabfc5ebd936d9befee48"
    }
  }
]